Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil

Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil

This study aims to describe in detail the patient journey from diagnosis to the beginning of treatment and patterns of care of hormone receptor- positive, HER2-negative de novo or recurrent metastatic breast cancer between January 2018 and December 2020 in Brazil.

Inclusion Criteria:

• Women ≥18 years old
• Histologically confirmed hormone receptor-positive HER2-negative invasive breast cancer
• Hormone receptor-positive defined as 1% to 100% of tumor nuclei positive for Estrogen - - Receptor and/or Progesterone Receptor, as per ASCO/CAP Guideline 2020 - or Allred score of ≥3
• HER2-negative defined as IHC result is 0/1+ or 2+ with ISH negative as per ASCO/CAP Guideline 2018
• Diagnosed with de novo or recurrent metastatic breast cancer between January 2018 -and December 2020
• Public health system or private health system

Exclusion Criteria:

• Male Breast Cancer
• First-line treatment for mBC received through clinical trial